NEW YORK (GenomeWeb News) – Pressure BioSciences today said that its revenues for the second quarter improved 10 percent year over year, paced by a 60 percent growth in grant revenues.

For the three months ended June 30, the South Easton, Mass.-based firm recorded total revenues of $357,736, up from $324,908 a year ago. While revenues from PCT products and services retreated 8 percent to $196,522 from $224,384, grant revenues increased to $161,214 from $100,524.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.